SCHEMBL1360006

SCHEMBL1360006

C=C[13CH]N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30634 1.00
SCHEMBL15422 0.72
SCHEMBL3960199 0.72
SCHEMBL2181354 0.72
Butadiene SCHEMBL3666279 0.67
SCHEMBL23926390 0.67
Iodide SCHEMBL8464248 0.67
Water SCHEMBL9289518 0.67
SCHEMBL132317 0.67
SCHEMBL6712915 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067603-B2 Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse SOLVAY PHARMACEUTICALS B.V. (NL) 2011-11-29 US claimed
US-7851630-B2 Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS B.V. (NL) 2010-12-14 US claimed
EP-1670457-A1 BICYCL 3.1.1]HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS Solvay Pharmaceuticals B.V. (NL) 2006-06-21 EP claimed
EP-1664017-A1 BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS Solvay Pharmaceuticals B.V. (NL) 2006-06-07 EP claimed
WO-2005032547-A1 BICYCLO`3.1.1!HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS SOLVAY PHARMACEUTICALS B.V. (NL) 2005-04-14 WO claimed
US-20050075355-A1 Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS B.V. 2005-04-07 US claimed
US-20050070528-A1 Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS B.V. 2005-03-31 US claimed
WO-2005028466-A1 BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS SOLVAY PHARMACEUTICALS B.V. (NL) 2005-03-31 WO claimed
US-8067603-B2 Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse SOLVAY PHARMACEUTICALS B.V. (NL) 2011-11-29 US disclosed
US-7851630-B2 Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS B.V. (NL) 2010-12-14 US disclosed
EP-1670457-A1 BICYCL 3.1.1]HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS Solvay Pharmaceuticals B.V. (NL) 2006-06-21 EP disclosed
EP-1664017-A1 BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS Solvay Pharmaceuticals B.V. (NL) 2006-06-07 EP disclosed
WO-2005032547-A1 BICYCLO`3.1.1!HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS SOLVAY PHARMACEUTICALS B.V. (NL) 2005-04-14 WO disclosed
US-20050075355-A1 Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS B.V. 2005-04-07 US disclosed
US-20050070528-A1 Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS B.V. 2005-03-31 US disclosed
WO-2005028466-A1 BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS SOLVAY PHARMACEUTICALS B.V. (NL) 2005-03-31 WO disclosed